Svenson G, Strandberg L E, Lindvall B, Erhardt L
Department of Medicine, Karolinska Institute, Danderyd Hospital, Sweden.
Br Heart J. 1988 Dec;60(6):489-96. doi: 10.1136/hrt.60.6.489.
Dopexamine is a new vasodilator with a combination of dopamine receptor and beta 2 adrenoreceptor agonist properties. Its haemodynamic effects were assessed after dose titration and during infusion for up to 24 hours in 15 patients with heart failure after acute myocardial infarction. At the initial titration a dose of 1 micrograms/kg/min produced a 25% decrease in the systemic vascular resistance index and a 32% increase in cardiac index. Stroke volume index and heart rate increased by 23% and 9% respectively. Left ventricular filling pressures and mean blood pressures were not affected. The short term effects were well sustained during the long term infusion and tolerance did not develop. Administration of dopexamine to patients with heart failure after acute myocardial infarction augments cardiac performance at rest.
多培沙明是一种新型血管扩张剂,兼具多巴胺受体和β2肾上腺素能受体激动剂特性。在15例急性心肌梗死后心力衰竭患者中,经剂量滴定并持续输注长达24小时后,评估了其血流动力学效应。在初始滴定时,1微克/千克/分钟的剂量使全身血管阻力指数降低25%,心脏指数增加32%。每搏量指数和心率分别增加23%和9%。左心室充盈压和平均血压未受影响。在长期输注期间,短期效应得到良好维持,未出现耐受性。对急性心肌梗死后心力衰竭患者给予多培沙明可增强静息时的心脏功能。